• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

进入抑制剂：阻断病毒感染的有效手段。

Entry Inhibitors: Efficient Means to Block Viral Infection.

机构信息

School of Chemistry, Sambalpur University, Jyoti Vihar, Burla, Odisha, 768 019, India.

Centre of Excellence in Natural Products and Therapeutics, Sambalpur University, Jyoti Vihar, Burla, Odisha, 768 019, India.

出版信息

J Membr Biol. 2020 Oct;253(5):425-444. doi: 10.1007/s00232-020-00136-z. Epub 2020 Aug 30.

DOI:10.1007/s00232-020-00136-z
PMID:32862236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7456447/
Abstract

The emerging and re-emerging viral infections are constant threats to human health and wellbeing. Several strategies have been explored to develop vaccines against these viral diseases. The main effort in the journey of development of vaccines is to neutralize the fusion protein using antibodies. However, significant efforts have been made in discovering peptides and small molecules that inhibit the fusion between virus and host cell, thereby inhibiting the entry of viruses. This class of inhibitors is called entry inhibitors, and they are extremely efficient in reducing viral infection as the entry of the virus is considered as the first step of infection. Nevertheless, these inhibitors are highly selective for a particular virus as antibody-based vaccines. The recent COVID-19 pandemic lets us ponder to shift our attention towards broad-spectrum antiviral agents from the so-called 'one bug-one drug' approach. This review discusses peptide and small molecule-based entry inhibitors against class I, II, and III viruses and sheds light on broad-spectrum antiviral agents.

摘要

新兴和再现的病毒感染是对人类健康和福祉的持续威胁。已经探索了几种策略来开发针对这些病毒性疾病的疫苗。疫苗开发过程中的主要努力是使用抗体中和融合蛋白。然而，人们在发现抑制病毒与宿主细胞融合从而抑制病毒进入的肽和小分子方面做出了巨大努力。这类抑制剂称为进入抑制剂，由于病毒进入被认为是感染的第一步，因此它们在降低病毒感染方面非常有效。然而，与基于抗体的疫苗不同，这些抑制剂对特定病毒具有高度选择性。最近的 COVID-19 大流行让我们考虑将注意力从所谓的“一种病菌一种药物”方法转移到广谱抗病毒药物上。这篇综述讨论了针对 I 型、II 型和 III 型病毒的基于肽和小分子的进入抑制剂，并探讨了广谱抗病毒药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/30a452706530/232_2020_136_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/b6ea8ab63e52/232_2020_136_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/4d75f9009955/232_2020_136_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/3bc40dfb79dc/232_2020_136_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/863d6fcca0f4/232_2020_136_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/754ceaf8ace8/232_2020_136_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/c4e64581f09e/232_2020_136_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/5f2f2d331107/232_2020_136_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/84ba7931f1f6/232_2020_136_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/4aa0de2d7a54/232_2020_136_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/bfeb74ac0000/232_2020_136_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/a804ab4af9e1/232_2020_136_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/7cf955d370e6/232_2020_136_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/ba8482e50e2f/232_2020_136_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/30a452706530/232_2020_136_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/b6ea8ab63e52/232_2020_136_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/4d75f9009955/232_2020_136_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/3bc40dfb79dc/232_2020_136_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/863d6fcca0f4/232_2020_136_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/754ceaf8ace8/232_2020_136_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/c4e64581f09e/232_2020_136_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/5f2f2d331107/232_2020_136_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/84ba7931f1f6/232_2020_136_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/4aa0de2d7a54/232_2020_136_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/bfeb74ac0000/232_2020_136_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/a804ab4af9e1/232_2020_136_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/7cf955d370e6/232_2020_136_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/ba8482e50e2f/232_2020_136_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d7/7456447/30a452706530/232_2020_136_Fig14_HTML.jpg

相似文献

1
Entry Inhibitors: Efficient Means to Block Viral Infection.进入抑制剂：阻断病毒感染的有效手段。
J Membr Biol. 2020 Oct;253(5):425-444. doi: 10.1007/s00232-020-00136-z. Epub 2020 Aug 30.
2
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.针对高融合活性新兴冠状病毒 SARS-CoV-2 的有效膜融合抑制剂设计。
J Virol. 2020 Jul 1;94(14). doi: 10.1128/JVI.00635-20.
3
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals.从 COVID-19 大流行中吸取的惨痛教训：需要广谱、宿主导向的抗病毒药物。
J Transl Med. 2020 Oct 15;18(1):390. doi: 10.1186/s12967-020-02476-9.
4
Cationic drugs and COVID-19.阳离子药物与 COVID-19。
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420966078. doi: 10.1177/2058738420966078.
5
Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.抑制病毒生命周期早期阶段的潜在抗 COVID-19 治疗药物：结构、机制和临床试验。
Int J Mol Sci. 2020 Jul 23;21(15):5224. doi: 10.3390/ijms21155224.
6
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Mar 11;16(685):510-511.
7
Potent antiviral effect of silver nanoparticles on SARS-CoV-2.银纳米粒子对 SARS-CoV-2 的强大抗病毒作用。
Biochem Biophys Res Commun. 2020 Nov 26;533(1):195-200. doi: 10.1016/j.bbrc.2020.09.018. Epub 2020 Sep 11.
8
LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.LY6E限制包括当前大流行的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在内的人类冠状病毒的进入。
J Virol. 2020 Aug 31;94(18). doi: 10.1128/JVI.00562-20.
9
Drug Discovery Strategies for SARS-CoV-2.针对 SARS-CoV-2 的药物研发策略。
J Pharmacol Exp Ther. 2020 Oct;375(1):127-138. doi: 10.1124/jpet.120.000123. Epub 2020 Jul 28.
10
Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.通过计算方法鉴定一种重新利用的药物作为人类冠状病毒SARS-CoV-2刺突蛋白的抑制剂。
J Biosci. 2020;45(1). doi: 10.1007/s12038-020-00102-w.

引用本文的文献

1
Screening of Medicinal Herbs Identifies and Its Bioactive Component Caffeic Acid as SARS-CoV-2 Entry Inhibitors.药用植物筛选鉴定出其生物活性成分咖啡酸作为新型冠状病毒2型进入抑制剂。
Viruses. 2025 Aug 5;17(8):1086. doi: 10.3390/v17081086.
2
Membrane-Targeting Antivirals.膜靶向抗病毒药物。
Int J Mol Sci. 2025 Jul 28;26(15):7276. doi: 10.3390/ijms26157276.
3
Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation.利用抗病毒肽：从分子机制到临床转化

本文引用的文献

1
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.针对高融合活性新兴冠状病毒 SARS-CoV-2 的有效膜融合抑制剂设计。
J Virol. 2020 Jul 1;94(14). doi: 10.1128/JVI.00635-20.
2
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.强效泛冠状病毒融合抑制剂抑制 SARS-CoV-2（前称 2019-nCoV）感染，该抑制剂针对病毒的刺突蛋白，具有很强的介导膜融合能力。
Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30.
3
Curr Res Pharmacol Drug Discov. 2025 Jul 15;9:100228. doi: 10.1016/j.crphar.2025.100228. eCollection 2025.
4
Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections.靶向病原体的生物类似药：对其在细菌、真菌、寄生虫和病毒感染中作用的全面综述
Pharmaceutics. 2025 Apr 28;17(5):581. doi: 10.3390/pharmaceutics17050581.
5
EDP-323, a First-In-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults.EDP-323，一种用于治疗呼吸道合胞病毒（RSV）的一流每日一次口服L蛋白抑制剂：一项针对健康成年人的1期研究结果
Clin Transl Sci. 2025 May;18(5):e70231. doi: 10.1111/cts.70231.
6
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics.结构病毒学：抗病毒治疗药物研发中的关键决定因素
Viruses. 2025 Mar 14;17(3):417. doi: 10.3390/v17030417.
7
Developing peptide-based fusion inhibitors as an antiviral strategy utilizing coronin 1 as a template.以冠蛋白1为模板开发基于肽的融合抑制剂作为一种抗病毒策略。
RSC Med Chem. 2024 Oct 2;16(1):125-36. doi: 10.1039/d4md00523f.
8
The Enigmatic Interplay of Interleukin-10 in the Synergy of HIV Infection Comorbid with Preeclampsia.白细胞介素-10 在 HIV 感染合并子痫前期协同作用中的神秘相互作用。
Int J Mol Sci. 2024 Aug 30;25(17):9434. doi: 10.3390/ijms25179434.
9
Antiviral Activities of Mastoparan-L-Derived Peptides against Human Alphaherpesvirus 1.蜂毒素衍生肽对人单纯疱疹病毒 1 的抗病毒活性。
Viruses. 2024 Jun 12;16(6):948. doi: 10.3390/v16060948.
10
In Silico Assessment of Chemical Disinfectants on Surface Proteins Unveiled Dissimilarity in Antiviral Efficacy and Suitability towards Pathogenic Viruses.计算机模拟评估化学消毒剂对表面蛋白的影响揭示了其抗病毒功效的差异和对致病性病毒的适用性。
Int J Mol Sci. 2024 May 30;25(11):6009. doi: 10.3390/ijms25116009.
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
4
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.2019新型冠状病毒的融合机制及靶向刺突蛋白HR1结构域的融合抑制剂
Cell Mol Immunol. 2020 Jul;17(7):765-767. doi: 10.1038/s41423-020-0374-2. Epub 2020 Feb 11.
5
Membrane Cholesterol Modulates Oligomeric Status and Peptide-Membrane Interaction of Severe Acute Respiratory Syndrome Coronavirus Fusion Peptide.膜胆固醇调节严重急性呼吸综合征冠状病毒融合肽的寡聚状态和肽-膜相互作用。
J Phys Chem B. 2019 Dec 19;123(50):10654-10662. doi: 10.1021/acs.jpcb.9b08455. Epub 2019 Dec 6.
6
Targeting viral entry as a strategy for broad-spectrum antivirals.将病毒入侵作为广谱抗病毒药物的一种策略。
F1000Res. 2019 Sep 12;8. doi: 10.12688/f1000research.19694.1. eCollection 2019.
7
Cholesterol alters the inhibitory efficiency of peptide-based membrane fusion inhibitor.胆固醇改变基于肽的膜融合抑制剂的抑制效率。
Biochim Biophys Acta Biomembr. 2019 Dec 1;1861(12):183056. doi: 10.1016/j.bbamem.2019.183056. Epub 2019 Aug 29.
8
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.基于蛋白质和肽的 HIV 进入抑制剂的开发，针对 gp120 或 gp41。
Viruses. 2019 Aug 1;11(8):705. doi: 10.3390/v11080705.
9
Cholesterol Modulates Membrane Properties and the Interaction of gp41 Fusion Peptide To Promote Membrane Fusion.胆固醇调节膜性质和 gp41 融合肽的相互作用以促进膜融合。
J Phys Chem B. 2019 Aug 22;123(33):7113-7122. doi: 10.1021/acs.jpcb.9b04577. Epub 2019 Aug 8.
10
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.一种针对人冠状病毒刺突 HR1 结构域的泛冠状病毒融合抑制剂。
Sci Adv. 2019 Apr 10;5(4):eaav4580. doi: 10.1126/sciadv.aav4580. eCollection 2019 Apr.